This is a small, early-stage R&D collaboration for a mega-cap biotech, no near-term revenue or earnings impact. Monitor for future milestone announcements or clinical data readouts on AHC candidates, but no immediate trading catalyst.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $629.34entry
- T+1 · 6mo ago +0.07%α +0.72% · $629.76
- T+5 · 6mo ago +0.45%α −1.17% · $632.17
- T+20 · 5mo ago −2.28%α −4.47% · $614.98
- T+60 · 3mo ago +26.80%α +22.22% · $797.99
Price Chart
How similar events traded
Executive Summary
Regeneron announced a strategic research collaboration with Parabilis Medicines to discover Antibody-Helicon Conjugates (AHCs) targeting previously undruggable intracellular proteins. Regeneron will pay Parabilis $125M upfront ($50M cash + $75M equity commitment), with up to ~$2.2B in additional milestone payments plus tiered royalties. The deal is a modest R&D bet for a $73B biotech, the upfront is ~0.17% of market cap, but opens a novel therapeutic modality.
Key Financial Metrics
Key Facts
- Regeneron pays $125M to Parabilis: $50M upfront + $75M equity commitment
- Up to ~$2.2B in total milestone payments plus tiered royalties up to low double-digits
- Collaboration focuses on Antibody-Helicon Conjugates (AHCs) for intracellular targets
- Five initial targets with option to add more upon additional option payments
- Regeneron responsible for development, manufacturing, and worldwide commercialization
Financial Impact
Upfront cost of $125M (~0.17% of REGN's $73.2B market cap); total deal value up to ~$2.2B in milestones, but these are contingent and distant
Risk Factors
- Helicon platform is unproven in humans; AHCs are a novel modality with high technical risk
- Milestone payments are contingent on development success, most early-stage collaborations never reach commercialization
- No change to Regeneron's core revenue drivers (Eylea, Dupixent, Libtayo)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296473 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers